AR074239A1 - Sales de (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidroxipiran-4-iloxi)piridina, su sintesis e intermediarios de la misma, composicion farmaceutica que las com-prende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por nnr - Google Patents
Sales de (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidroxipiran-4-iloxi)piridina, su sintesis e intermediarios de la misma, composicion farmaceutica que las com-prende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por nnrInfo
- Publication number
- AR074239A1 AR074239A1 ARP090104608A ARP090104608A AR074239A1 AR 074239 A1 AR074239 A1 AR 074239A1 AR P090104608 A ARP090104608 A AR P090104608A AR P090104608 A ARP090104608 A AR P090104608A AR 074239 A1 AR074239 A1 AR 074239A1
- Authority
- AR
- Argentina
- Prior art keywords
- vinyl
- pyrrolidin
- tetrahydropyran
- yloxy
- pyridine
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229920002554 vinyl polymer Polymers 0.000 title 1
- ORGHESHFQPYLAO-UHFFFAOYSA-N vinyl radical Chemical class C=[CH] ORGHESHFQPYLAO-UHFFFAOYSA-N 0.000 title 1
- GZPNWUVQYHRUPP-AORQRIRUSA-N 3-(oxan-4-yloxy)-5-[(e)-2-[(3r)-pyrrolidin-3-yl]ethenyl]pyridine Chemical compound C1NCC[C@@H]1\C=C\C1=CN=CC(OC2CCOCC2)=C1 GZPNWUVQYHRUPP-AORQRIRUSA-N 0.000 abstract 5
- 239000012453 solvate Substances 0.000 abstract 4
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- NTOIKDYVJIWVSU-WOJBJXKFSA-N (2r,3r)-2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-WOJBJXKFSA-N 0.000 abstract 1
- -1 1- (tert-butoxycarbonyl) pyrrolidin-3-yl Chemical group 0.000 abstract 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 abstract 1
- YVURRNSWNKXGGT-ZETCQYMHSA-N 2-[(3r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-3-yl]propanedioic acid Chemical compound CC(C)(C)OC(=O)N1CC[C@H](C(C(O)=O)C(O)=O)C1 YVURRNSWNKXGGT-ZETCQYMHSA-N 0.000 abstract 1
- GZPNWUVQYHRUPP-ZIYVKSGCSA-N 3-(oxan-4-yloxy)-5-[(e)-2-[(3s)-pyrrolidin-3-yl]ethenyl]pyridine Chemical compound C1NCC[C@H]1\C=C\C1=CN=CC(OC2CCOCC2)=C1 GZPNWUVQYHRUPP-ZIYVKSGCSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- MOZHCCJHNWLXIE-RRVIAKDDSA-N oxalic acid;3-(oxan-4-yloxy)-5-[(e)-2-[(3r)-pyrrolidin-3-yl]ethenyl]pyridine Chemical compound OC(=O)C(O)=O.C1NCC[C@@H]1\C=C\C1=CN=CC(OC2CCOCC2)=C1 MOZHCCJHNWLXIE-RRVIAKDDSA-N 0.000 abstract 1
- OYRWWTPZWOPIOO-UHFFFAOYSA-N tert-butyl 3-(2-hydroxyethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)C1 OYRWWTPZWOPIOO-UHFFFAOYSA-N 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
(R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, sus formas de sales y con los procesos para la produccion en escala comercial de estos compuestos con pureza y calidad suficiente para su uso en composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la modulacion de los receptores de acetilcolina nicotínico neuronal (NNR). Reivindicacion 1: Mono-L-malato de (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 2: Hemigalactarato de(R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 3: Oxalato de (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 4: Di-p-toluoil-D-tartrato de (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o un hidrato o solvato de él. Reivindicacion 5: (R)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina, o una sal farmacéuticamente aceptable de ella sustancialmente libre de (S)-3-((E)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina. Reivindicacion 16: Un compuesto que se selecciona de: ( R)-2-(1-(terc-butoxicarbonil)pirrolidin-3-il)malonato de dietilo; Ácido ( R)-2-(1-(terc-butoxicarbonil)pirrolidin-3-il)malonico; (R)-3- (2-hidroxietil) pirrolidina-1-carboxilato de terc-butilo; y (R)-3-(2-yodoetil)pirrolidina-1-carboxilato de terc-butilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11888508P | 2008-12-01 | 2008-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074239A1 true AR074239A1 (es) | 2010-12-29 |
Family
ID=41549744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104608A AR074239A1 (es) | 2008-12-01 | 2009-11-30 | Sales de (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidroxipiran-4-iloxi)piridina, su sintesis e intermediarios de la misma, composicion farmaceutica que las com-prende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por nnr |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8153821B2 (es) |
| EP (3) | EP2358705A1 (es) |
| JP (2) | JP5698673B2 (es) |
| KR (2) | KR20110094318A (es) |
| CN (2) | CN102232072B (es) |
| AR (1) | AR074239A1 (es) |
| AU (2) | AU2009322630A1 (es) |
| BR (2) | BRPI0922152A2 (es) |
| CA (2) | CA2744191A1 (es) |
| CL (2) | CL2009002146A1 (es) |
| CO (1) | CO6382158A2 (es) |
| EA (1) | EA021054B1 (es) |
| EC (1) | ECSP11011135A (es) |
| ES (1) | ES2403022T3 (es) |
| IL (2) | IL212796A0 (es) |
| MX (2) | MX2011005713A (es) |
| MY (1) | MY159040A (es) |
| NZ (1) | NZ593058A (es) |
| PE (1) | PE20100467A1 (es) |
| RU (1) | RU2507197C2 (es) |
| SA (1) | SA109300715B1 (es) |
| SG (2) | SG171432A1 (es) |
| TW (1) | TW201024283A (es) |
| UA (1) | UA106217C2 (es) |
| UY (1) | UY32278A (es) |
| WO (2) | WO2010065447A2 (es) |
| ZA (1) | ZA201103497B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
| PL3279195T3 (pl) * | 2008-12-01 | 2020-12-14 | Oyster Point Pharma, Inc. | Synteza i nowe postacie soli (R)-5-((E)-2-pirolidyn-3-ylowinylo)pirymidyny |
| WO2013116371A1 (en) * | 2012-01-30 | 2013-08-08 | Roar Biomedical Inc. | Ex vivo plasma enzyme activity assay using inhibitors as a negative control |
| WO2014123899A1 (en) | 2013-02-05 | 2014-08-14 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| US20160262372A1 (en) * | 2015-03-13 | 2016-09-15 | Cornell Kunz | Extermination Treatment Appliance And Method |
| NZ746468A (en) | 2016-04-07 | 2023-06-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK94393A3 (en) * | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| JP3745433B2 (ja) * | 1995-02-02 | 2006-02-15 | 第一製薬株式会社 | 複素環式化合物 |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| CZ83499A3 (cs) * | 1996-09-13 | 1999-07-14 | Schering Corporation | Tricyklické sloučeniny, farmaceutický prostředek je obsahující a jejich použití |
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| JPH1171345A (ja) * | 1997-08-30 | 1999-03-16 | Nippon Nohyaku Co Ltd | 光学活性なピロリジン誘導体及びその中間体並びにそれらの製造法 |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| GB9821503D0 (en) | 1998-10-02 | 1998-11-25 | Novartis Ag | Organic compounds |
| AU2001271027B2 (en) * | 2000-07-11 | 2005-07-07 | Msd K.K. | Ester derivatives |
| WO2003013526A1 (en) * | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
| US7098331B2 (en) | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
| WO2007054777A1 (en) * | 2005-11-09 | 2007-05-18 | Orchid Chemicals & Pharmaceuticals Limited | Depletion of isomer in cephalosporin antibiotic |
| WO2007134298A2 (en) * | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
-
2009
- 2009-11-25 TW TW098140046A patent/TW201024283A/zh unknown
- 2009-11-30 SG SG2011038528A patent/SG171432A1/en unknown
- 2009-11-30 AU AU2009322630A patent/AU2009322630A1/en not_active Abandoned
- 2009-11-30 JP JP2011538712A patent/JP5698673B2/ja not_active Expired - Fee Related
- 2009-11-30 ES ES09775409T patent/ES2403022T3/es active Active
- 2009-11-30 MY MYPI2011002085A patent/MY159040A/en unknown
- 2009-11-30 EP EP09775410A patent/EP2358705A1/en not_active Withdrawn
- 2009-11-30 KR KR1020117014805A patent/KR20110094318A/ko not_active Ceased
- 2009-11-30 NZ NZ593058A patent/NZ593058A/xx not_active IP Right Cessation
- 2009-11-30 AR ARP090104608A patent/AR074239A1/es not_active Application Discontinuation
- 2009-11-30 CN CN200980148072.8A patent/CN102232072B/zh not_active Expired - Fee Related
- 2009-11-30 SG SG2011039575A patent/SG171876A1/en unknown
- 2009-11-30 MX MX2011005713A patent/MX2011005713A/es active IP Right Grant
- 2009-11-30 PE PE2009001282A patent/PE20100467A1/es not_active Application Discontinuation
- 2009-11-30 US US13/130,954 patent/US8153821B2/en active Active
- 2009-11-30 CL CL2009002146A patent/CL2009002146A1/es unknown
- 2009-11-30 UY UY0001032278A patent/UY32278A/es not_active Application Discontinuation
- 2009-11-30 AU AU2009322628A patent/AU2009322628A1/en not_active Abandoned
- 2009-11-30 WO PCT/US2009/066083 patent/WO2010065447A2/en not_active Ceased
- 2009-11-30 UA UAA201108205A patent/UA106217C2/ru unknown
- 2009-11-30 WO PCT/US2009/066092 patent/WO2010065449A1/en not_active Ceased
- 2009-11-30 CA CA2744191A patent/CA2744191A1/en not_active Abandoned
- 2009-11-30 JP JP2011538713A patent/JP5615836B2/ja not_active Expired - Fee Related
- 2009-11-30 RU RU2011127004/04A patent/RU2507197C2/ru active IP Right Revival
- 2009-11-30 EA EA201170736A patent/EA021054B1/ru not_active IP Right Cessation
- 2009-11-30 CN CN2009801478569A patent/CN102227406B/zh not_active Expired - Fee Related
- 2009-11-30 MX MX2011005712A patent/MX2011005712A/es not_active Application Discontinuation
- 2009-11-30 KR KR1020117014918A patent/KR20110094100A/ko not_active Abandoned
- 2009-11-30 CL CL2009002145A patent/CL2009002145A1/es unknown
- 2009-11-30 CA CA2744197A patent/CA2744197A1/en not_active Abandoned
- 2009-11-30 EP EP14191551.2A patent/EP2896619A1/en not_active Withdrawn
- 2009-11-30 BR BRPI0922152-2A patent/BRPI0922152A2/pt not_active IP Right Cessation
- 2009-11-30 EP EP09775409A patent/EP2358670B1/en active Active
- 2009-11-30 US US13/125,892 patent/US8633227B2/en not_active Expired - Fee Related
- 2009-11-30 BR BRPI0922630A patent/BRPI0922630A2/pt not_active IP Right Cessation
- 2009-12-05 SA SA109300715A patent/SA109300715B1/ar unknown
-
2011
- 2011-05-09 IL IL212796A patent/IL212796A0/en unknown
- 2011-05-09 IL IL212799A patent/IL212799A/en not_active IP Right Cessation
- 2011-05-12 ZA ZA2011/03497A patent/ZA201103497B/en unknown
- 2011-06-16 EC EC2011011135A patent/ECSP11011135A/es unknown
- 2011-06-17 CO CO11075843A patent/CO6382158A2/es active IP Right Grant
-
2013
- 2013-12-16 US US14/107,175 patent/US20140107163A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074239A1 (es) | Sales de (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidroxipiran-4-iloxi)piridina, su sintesis e intermediarios de la misma, composicion farmaceutica que las com-prende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por nnr | |
| PE20090964A1 (es) | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b | |
| CL2008002768A1 (es) | Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades. | |
| CO2022002842A2 (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| HRP20110962T1 (hr) | Derivati pirazolil-aminopiridina korisni kao inhibitori kinaze | |
| CR11061A (es) | Derivados de piridina | |
| DOP2010000242A (es) | Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina | |
| CR9462A (es) | Inhibidores de la dipeptidil peptidasa-iv | |
| UY31838A (es) | Derivados de quinoxalin- y quinolin-carboxamida | |
| ECSP077185A (es) | Derivados de piridina | |
| UY32156A (es) | Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones. | |
| UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
| EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
| AR051754A1 (es) | Metodos para preparar compuestos de indazol | |
| MX2007009372A (es) | Nuevos compuestos ii derivados de 2-piridina como inhibidores de elastasa neutrofila. | |
| TW200639156A (en) | New compounds | |
| ECSP099602A (es) | Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas | |
| AR056014A1 (es) | Compuesto 3-aminocarbazol, composicion farmaceutica que lo contiene y procedimiento para la preparacion del mismo | |
| AR056860A1 (es) | Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores | |
| AR041865A1 (es) | Derivados terapeuticos de prolina y su uso en el tratamiento de epilepsia y dolor | |
| MX355734B (es) | Formas cristalinas de clorhidrato de 1- (3-ter-butil-1-p-tolil-1h- pirazol-5-il)-3- (5-fluoro-2- (1- (2- hidroxietil) -indazol-5-iloxi) bencil) urea.. | |
| SE0401763D0 (sv) | Compounds | |
| PE20091344A1 (es) | Arilindenopirimidinas como antagonistas del receptor a2a de adenosina | |
| AR063233A1 (es) | Inhibidores de quinasas | |
| AR078960A1 (es) | Sales del acido 5-(aminopirimidin-4-il)-2-(2,4-dicloro fenil)-1h-pirrol-3-carboxilico como inhibidor de cdc7 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |